When thinking about the future of pharma these days, we often find ourselves looking not at the big-name companies, but at the smaller firms at the cutting-edge of the industry. (It’s not just by chance that the industry has been dominated by M&A for the last couple of years.)
There is still time to fill out the MCQ and submit your essay for the prestigious PharmaTimes International Clinical Researcher of theYear competition - but with less than two weeks to go until entries close, you should start the process now.
“Urgent action” is required to boost the productivity of the UK’s R&D model, which is grappling with “unprecedented pressure”, claims a new report by Medicines Discovery Catapult and the BioIndustry Association.
Digitally-augmented multi-channel engagement has proved to be a useful approach for working with patients. However, it is easy for developers to default to a patient-facing website or an app that looks good and sounds impressive, but in practice doesn’t supply what patients want and need
The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.